/PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced that long-term data from its Phase 2 trial in...
#Product Stage
Nov 24, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has...
#Product Stage #FDA approved/pending approval
Sep 30, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...
#Product Stage #FDA approved/pending approval
Sep 2, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct
#Customers
Dec 9, 2020
www.calcalist.co.il
אמורפיקל שמפיקה סידן מסרטנים כחולים יוצאת לגיוס של 30 מיליון דולר לפי שווי של 160 מיליון דולר
/PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced that long-term data from its Phase 2 trial in...
#Product Stage
Nov 24, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has...
#Product Stage #FDA approved/pending approval
Sep 30, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...
#Product Stage #FDA approved/pending approval
Sep 2, 2025
www.prnewswire.com
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct
#Customers
Dec 9, 2020
www.calcalist.co.il
אמורפיקל שמפיקה סידן מסרטנים כחולים יוצאת לגיוס של 30 מיליון דולר לפי שווי של 160 מיליון דולר